Ensysce Biosciences
Update in progressENSC (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ensysce Biosciences is a clinical-stage pharmaceutical company focused on safer pain relief and treatment of opioid-related disorders in the United States. It uses the Trypsin Activated Abuse Protection (TAAP) platform to release drugs only under specific physiological conditions, and the Multi-Pill Abuse Resistance (MPAR) platform for overdose protection. Lead PF614 is a TAAP oxycodone prodrug; PF614-MPAR combines PF614 with nafamostat. The company also develops PF8001 and PF8026 (amphetamine prodrugs for ADHD) and PF9001 for opioid use disorder. Founded in 2003, based in La Jolla, California.
Company score
- Sentiment
- 0.09
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.04
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!